We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Advanced Melanoma

Journal Scan / Research · September 23, 2021

Adjuvant Anti–PD-1 Antibody Treatment in Stage III/IV Melanoma Is Cost-Effective

Journal of the German Society of Dermatology: JDDG


Additional Info

Journal of the German Society of Dermatology: JDDG
Adjuvant Anti-PD-1 Antibody Treatment in Stage III/IV Melanoma: Real-World Experience and Health Economic Considerations
J Dtsch Dermatol Ges 2021 Jul 13;[EPub Ahead of Print], P Koelblinger, M Hoellwerth, MT Dernoscheg, L Koch, E Richtig, M Wanner, VA Nguyen, H Ostermann, JW Bauer, M Laimer

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading